Dosing & Uses
Dosage Forms & Strengths
tablet
- 3mg
Thrombocytopenia
Indicated for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure
Begin dosing 8-14 days prior to scheduled procedure
Patients should undergo their procedure 2-8 days after the last dose
Recommended dose: 3 mg PO qDay for 7 days
Also see Administration
Dosage Modifications
Renal impairment
- Mild-to-moderate (CrCl 30-90 mL/min): No clinically meaningful effects on the pharmacokinetics
- Severe (CrCl <30 mL/min) or hemodialysis: Limited data
Hepatic impairment
- Mild-to-moderate (Child-Pugh A or B): No clinically meaningful effects on the pharmacokinetics
- Severe (Child-Pugh C): Mean observed peak plasma concentration and AUC decreased by 20-30% in patients (compared with patients with Child-Pugh A and B); however, ranges for peak plasma concentration and AUC overlapped among patients with Child-Pugh class A, B, and C liver disease
Dosing Considerations
Investigated only as a single 7–day, once-daily dosing regimen in clinical trials in patients with chronic liver disease
Not to be administered to patients with chronic liver disease in an attempt to normalize platelet counts
Monitoring
- Obtain a platelet count prior to initiating and not more than 2 days before the procedure
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (0)
Minor (0)
Adverse Effects
1-10%
Headache (5%)
Portal vein thrombosis (1%)
Warnings
Contraindications
None
Cautions
Thrombotic or thromboembolic complications
- Thrombopoietin (TPO) receptor agonists, such as lusutrombopag, have been associated with thrombotic and thromboembolic complications (eg, portal vein thrombosis) in patients with chronic liver disease
- Consider the potential increased thrombotic risk when administering drug to patients with known risk factors for thromboembolism (eg, genetic prothrombotic conditions [factor V Leiden, prothrombin 20210A, antithrombin deficiency, or protein C or S deficiency])
- In patients with ongoing or prior thrombosis or absence of hepatopetal blood flow, use lusutrombopag if the potential benefit justifies the potential risk
- Should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts
Pregnancy
Pregnancy
There are no available data on use in pregnant women to inform a drug-associated risk
Animal data
- In animal reproduction studies, oral administration of lusutrombopag to pregnant rats during organogenesis and the lactation period resulted in adverse developmental outcomes
- These finding were observed at exposures based on AUC that were substantially higher than the AUC observed in patients (~89 times) at the recommended clinical dose of 3 mg qDay; advise pregnant women of the potential risk to a fetus
Lactation
There is no information on the presence of lusutrombopag in human milk, the effects on the breastfed child, and the effects on milk production
Drug was present in the milk of lactating rats
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Clinical considerations
- Lactating women should interrupt breastfeeding and pump and discard breast milk during treatment and for 28 days after the last dose in order to minimize exposure to a breastfed child
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Thrombopoietin (TPO) receptor agonist
Orally bioavailable, small molecule that interacts with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation
Absorption
Peak plasma concentration: 111 ng/mL
Peak plasma time: 6-8 hr
AUC: 2931 ng·hr/mL
Food effect
- AUC and peak plasma concentration were not affected when coadministered with a high–fat meal (~900 calories [total calories], with 500, 250, and 150 calories from fat, carbohydrate, and protein, respectively)
Distribution
Vd: 39.5 L
Protein binding: >99.9%
Metabolism
Metabolized by CYP4 enzymes, including CYP4A11
Elimination
Half-life: 27 hr
Clearance: 1.1 L/hr
Excretion: Feces (83%, 16% [unchanged]); Urine (~1%)
Administration
Oral Administration
Administer orally once a day with or without food for 7 days
Missed dose: Take the missed dose as soon as possible on the same day and return to the normal schedule the following day
Storage
Store tablets in original package at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F)
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Mulpleta oral - | 3 mg tablet | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.